Shots:
- Novartis has reported interim P-III (PSMAddition) trial data assessing Pluvicto + SoC (ARPI + ADT) vs SoC in PSMA+ mHSPC adults, with pts switching to Pluvicto upon confirmation of radiographic progression & per physician’s discretion
- Trial met its 1EP of improved rPFS, with favorable OS trend (2EP) observed; data to be shared in future meeting & will be submitted for regulatory review in H2’25 based on the FDA feedback
- Pluvicto (IV) delivers lutetium-177 to PSMA-expressing target cells incl. prostate cancer cells, where its radioactive emissions damage targeted & nearby cells, disrupting replication & triggering apoptosis
Ref: Global News Wire | Image: Novartis | Press Release
Related News:- Novartis to Acquire Regulus Therapeutics for ~$1.7B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
